Cytovance Biologics, Pamlico Biopharma Enter Into Manufacturing Agreement

Cytovance Biologics Inc., a full-service CMO of mammalian and microbial biologics, has entered into a development and manufacturing agreement with Pamlico Biopharma Inc., an Oklahoma City-based clinical stage biopharmaceutical company. Pamlico Biopharma has developed a group of three human IgG monoclonal antibodies intended for the treatment of Streptococcus pneumoniae infections. Pamlico has contracted Cytovance Biologics as its CMO to develop a production cell line from the protein's amino acid sequence for GMP manufacture of phase I clinical material. Read the full story